Oral Bioavailability of Posaconazole in Fasted Healthy S

Clinical Pharmacokinetics

44, 211-220

DOI: 10.2165/00003088-200544020-00006

Citation Report

#	Article	IF	Citations
1	Posaconazole: a broad-spectrum triazole antifungal. Lancet Infectious Diseases, The, 2005, 5, 775-785.	4.6	253
2	Posaconazole. Drugs, 2005, 65, 1553-1567.	4.9	144
3	Posaconazole: clinical pharmacology and potential for management of fungal infections. Expert Review of Anti-Infective Therapy, 2005, 3, 467-487.	2.0	98
4	Newer triazole antifungal agents: pharmacology, spectrum, clinical efficacy and limitations. Expert Opinion on Investigational Drugs, 2006, 15, 579-602.	1.9	77
5	HPLC analysis of the antifungal agent posaconazole in patients with haematological diseases. Mycoses, 2006, 49, 17-22.	1.8	36
6	Posaconazole Is Effective as Salvage Therapy in Zygomycosis: A Retrospective Summary of 91 Cases. Clinical Infectious Diseases, 2006, 42, e61-e65.	2.9	553
7	Pharmacokinetics and Safety of Oral Posaconazole in Neutropenic Stem Cell Transplant Recipients. Antimicrobial Agents and Chemotherapy, 2006, 50, 1993-1999.	1.4	135
8	Head-to-Head Comparison of the Activities of Currently Available Antifungal Agents against 3,378 Spanish Clinical Isolates of Yeasts and Filamentous Fungi. Antimicrobial Agents and Chemotherapy, 2006, 50, 917-921.	1.4	279
9	Pharmacokinetics, Safety, and Efficacy of Posaconazole in Patients with Persistent Febrile Neutropenia or Refractory Invasive Fungal Infection. Antimicrobial Agents and Chemotherapy, 2006, 50, 658-666.	1.4	264
10	Effects of Age, Gender, and Race/Ethnicity on the Pharmacokinetics of Posaconazole in Healthy Volunteers. Antimicrobial Agents and Chemotherapy, 2007, 51, 495-502.	1.4	81
11	Posaconazole: A Broad-Spectrum Triazole Antifungal Agent. Clinical Infectious Diseases, 2007, 45, 1610-1617.	2.9	201
12	Clinical Pharmacokinetics of Systemically Administered Antimycotics. Current Clinical Pharmacology, 2007, 2, 37-58.	0.2	68
13	Posaconazole: a next-generation triazole antifungal. Future Microbiology, 2007, 2, 231-243.	1.0	36
14	Posaconazole Plasma Concentrations in Juvenile Patients with Invasive Fungal Infection. Antimicrobial Agents and Chemotherapy, 2007, 51, 812-818.	1.4	153
15	Posaconazole Oral Suspension. Hospital Pharmacy, 2007, 42, 57-72.	0.4	1
16	Antimicrobial resistance prevention initiativeâ€"an update: Proceedings of an expert panel on resistance. American Journal of Infection Control, 2007, 35, S1-S23.	1.1	37
17	Antimicrobial Resistance Prevention Initiativeâ€"An Update: Proceedings of an Expert Panel on Resistance. American Journal of Medicine, 2007, 120, S4-S25.	0.6	48
18	Posaconazole: An extended-spectrum triazole antifungal agent. Clinical Therapeutics, 2007, 29, 1862-1886.	1.1	113

#	Article	IF	Citations
20	Clinical pharmacology of antifungal agents in pediatric patients. Expert Opinion on Pharmacotherapy, 2007, 8, 2465-2489.	0.9	20
21	Posaconazole: a new broad-spectrum antifungal agent. Expert Opinion on Pharmacotherapy, 2007, 8, 1167-1178.	0.9	39
22	Posaconazole (Noxafil): A New Triazole Antifungal Agent. Baylor University Medical Center Proceedings, 2007, 20, 188-196.	0.2	41
23	A sensitive liquid chromatography and mass spectrometry method for the determination of posaconazole in human plasma. Journal of Pharmaceutical and Biomedical Analysis, 2007, 43, 228-236.	1.4	78
24	Pharmacokinetics of Oral Posaconazole in Allogeneic Hematopoietic Stem Cell Transplant Recipients with Graft-versus-Host Disease. Pharmacotherapy, 2007, 27, 1627-1636.	1.2	163
26	Pharmacokinetic considerations for the use of newer antifungal agents. Current Fungal Infection Reports, 2008, 2, 5-11.	0.9	0
27	Antifungal agents â€“ clinical pharmacokinetics and drug interactions. Mycoses, 2008, 51, 7-18.	1.8	66
28	Pharmacokinetics of Oral Posaconazole in Neutropenic Patients Receiving Chemotherapy for Acute Myelogenous Leukemia or Myelodysplastic Syndrome. Pharmacotherapy, 2008, 28, 1223-1232.	1.2	82
29	Current Options in Antifungal Pharmacotherapy. Pharmacotherapy, 2008, 28, 614-645.	1.2	68
30	Posaconazole: An Oral Triazole with an Extended Spectrum of Activity. Annals of Pharmacotherapy, 2008, 42, 1429-1438.	0.9	42
32	New and Investigational Triazole Agents for the Treatment of Invasive Fungal Infections. Journal of Chemotherapy, 2008, 20, 661-671.	0.7	25
33	Progressive fusariosis: Unpredictable posaconazole bioavailability, and feasibility of recombinant interferon-gamma plus granulocyte macrophage-colony stimulating factor for refractory disseminated infection. Leukemia and Lymphoma, 2008, 49, 163-165.	0.6	33
34	Posaconazole as Salvage Therapy in Patients With Invasive Fungal Infections After Solid Organ Transplant. Transplantation, 2008, 86, 791-796.	0.5	71
35	Posaconazole in the management of refractory invasive fungal infections. Therapeutics and Clinical Risk Management, 2008, Volume 4, 747-757.	0.9	25
36	Posaconazole: A New Agent for the Prevention and Management of Severe, Refractory or Invasive Fungal Infections. Canadian Journal of Infectious Diseases and Medical Microbiology, 2008, 19, 297-305.	0.7	16
37	Prophylaxis of Invasive Fungal Infections: A Review of the Use of Posaconazole. Clinical Medicine Therapeutics, 2009, 1, CMT.S1948.	0.1	0
38	What Should Be the First-Choice Strategy To Maximize Posaconazole Exposure in Daily Clinical Practice?. Antimicrobial Agents and Chemotherapy, 2009, 53, 3608-3610.	1.4	7
39	Intrapulmonary Pharmacokinetics and Pharmacodynamics of Posaconazole at Steady State in Healthy Subjects. Antimicrobial Agents and Chemotherapy, 2009, 53, 703-707.	1.4	76

#	Article	IF	Citations
40	Therapeutic Drug Monitoring of Posaconazole: a Monocentric Study with 54 Adults. Antimicrobial Agents and Chemotherapy, 2009, 53, 5224-5229.	1.4	98
41	Posaconazole: A new oral antifungal agent with an expanded spectrum of activity. American Journal of Health-System Pharmacy, 2009, 66, 225-236.	0.5	32
42	Antifungal drugs: predicting clinical efficacy with pharmacodynamics. Expert Review of Clinical Pharmacology, 2009, 2, 373-379.	1.3	3
43	Antifungal Therapeutic Drug Monitoring: Established and Emerging Indications. Antimicrobial Agents and Chemotherapy, 2009, 53, 24-34.	1.4	442
44	Pharmacokinetics of Posaconazole Administered Orally or by Nasogastric Tube in Healthy Volunteers. Antimicrobial Agents and Chemotherapy, 2009, 53, 2960-2964.	1.4	35
45	Pharmacokinetics and Absorption of Posaconazole Oral Suspension under Various Gastric Conditions in Healthy Volunteers. Antimicrobial Agents and Chemotherapy, 2009, 53, 958-966.	1.4	311
46	Antifungal Therapy for Invasive Fungal Diseases in Allogeneic Stem Cell Transplant Recipients: An Update. Mycopathologia, 2009, 168, 313-327.	1.3	31
47	What is the role of therapeutic drug monitoring in antifungal therapy?. Current Infectious Disease Reports, 2009, 11, 439-446.	1.3	4
48	Tolerability and safety profile of posaconazole: evaluation of 18 controlled studies in healthy volunteers. Journal of Clinical Pharmacy and Therapeutics, 2009, 34, 301-311.	0.7	43
49	Antifungal therapy. , 2009, , 161-195.		15
50	Posaconazoleâ€™s impact on prophylaxis and treatment of invasive fungal infections: an update. Expert Review of Anti-Infective Therapy, 2009, 7, 165-181.	2.0	14
51	Use of posaconazole in the treatment of invasive fungal infections. Expert Review of Hematology, 2009, 2, 619-630.	1.0	10
52	Effects of oral posaconazole on the pharmacokinetics of sirolimus. Current Medical Research and Opinion, 2009, 25, 701-707.	0.9	50
53	Overview of Antifungal Agents. Clinics in Chest Medicine, 2009, 30, 203-215.	0.8	106
54	Antifungal Therapeutic Drug Monitoring. Current Fungal Infection Reports, 2010, 4, 158-167.	0.9	24
55	Clinical pharmacodynamics and pharmacokinetics of the antifungal extendedâ€spectrum triazole posaconazole: an overview. British Journal of Clinical Pharmacology, 2010, 70, 471-480.	1.1	66
56	Exposureâ€“Response of Posaconazole Used for Prophylaxis Against Invasive Fungal Infections: Evaluating the Need to Adjust Doses Based on Drug Concentrations in Plasma. Clinical Pharmacology and Therapeutics, 2010, 88, 115-119.	2.3	208
57	Clinically relevant drug interactions of current antifungal agents. Mycoses, 2010, 53, 95-113.	1.8	67

#	Article	IF	Citations
58	Clinical safety and tolerability issues in use of triazole derivatives in management of fungal infections. Drug, Healthcare and Patient Safety, 2010, 2, 27.	1.0	14
59	Therapeutic Drug Monitoring of Posaconazole in Hematology Patients: Experience with a New High-Performance Liquid Chromatography-Based Method. Antimicrobial Agents and Chemotherapy, 2010, 54, 4029-4032.	1.4	28
60	Steady-State Intrapulmonary Pharmacokinetics and Pharmacodynamics of Posaconazole in Lung Transplant Recipients. Antimicrobial Agents and Chemotherapy, 2010, 54, 3609-3613.	1.4	37
61	Efficacy of Posaconazole in a Murine Disseminated Infection by Can dida tropicalis. Antimicrobial Agents and Chemotherapy, 2010, 54, 530-532.	1.4	10
62	Factors Influencing Pharmacokinetics of Prophylactic Posaconazole in Patients Undergoing Allogeneic Stem Cell Transplantation. Antimicrobial Agents and Chemotherapy, 2010, 54, 207-212.	1.4	70
63	Population pharmacokinetics of posaconazole in neutropenic patients receiving chemotherapy for acute myelogenous leukemia or myelodysplastic syndrome. Current Medical Research and Opinion, 2010, 26, 397-405.	0.9	34
64	Ultra-Performance Liquid Chromatography Mass Spectrometry and Sensitive Bioassay Methods for Quantification of Posaconazole Plasma Concentrations after Oral Dosing. Antimicrobial Agents and Chemotherapy, 2010, 54, 5074-5081.	1.4	21
65	Pharmacokinetic/Pharmacodynamic Profile of Posaconazole. Clinical Pharmacokinetics, 2010, 49, 379-396.	1.6	210
66	Traditional and Emerging Antifungal Therapies. Proceedings of the American Thoracic Society, 2010, 7, 222-228.	3.5	41
67	Aspergillus Infections in the Critically Ill. Proceedings of the American Thoracic Society, 2010, 7, 204-209.	3.5	38
68	Antifungals to treatCandida albicans. Expert Opinion on Pharmacotherapy, 2010, 11, 2037-2048.	0.9	58
69	Posaconazole for the treatment of mucormycosis. International Journal of Antimicrobial Agents, 2011, 38, 465-473.	1.1	18
70	Effect of pH and Comedication on Gastrointestinal Absorption of Posaconazole. Clinical Pharmacokinetics, 2011, 50, 725-734.	1.6	114
71	Triazole Antifungal Agents in Invasive Fungal Infections. Drugs, 2011, 71, 2405-2419.	4.9	217
72	Current Concepts in Antifungal Pharmacology. Mayo Clinic Proceedings, 2011, 86, 805-817.	1.4	305
73	Overview of treatment options for invasive fungal infections. Medical Mycology, 2011, 49, 1-20.	0.3	47
74	Pharmacokineticâ€“pharmacodynamic optimization of triazole antifungal therapy. Current Opinion in Infectious Diseases, 2011, 24, S14-S29.	1.3	10
75	Pharmacology and metabolism of voriconazole and posaconazole in the treatment of invasive aspergillosis-review of the literature. European Journal of Medical Research, 2011, 16, 139.	0.9	59

#	Article	IF	Citations
77	Posaconazole: clinical pharmacokinetics and drug interactions. Mycoses, 2011, 54, 32-38.	1.8	25
78	Optimising absorption of posaconazole. Mycoses, 2011, 54, e775-e779.	1.8	17
79	Posaconazole: when and how? The clinicianâ€™s view. Mycoses, 2012, 55, 110-122.	1.8	27
80	Antifungal Pharmacokinetics and Dosing Considerations in Burn Patients. Current Fungal Infection Reports, 2011, 5, 67-74.	0.9	0
81	Update on Antifungal Drug Dosing and Therapeutic Drug Monitoring. Current Fungal Infection Reports, 2011, 5, 92-102.	0.9	3
82	Poor Absorption of High-Dose Posaconazole in Pediatric Bone Marrow Transplant Patients. Annals of Pharmacotherapy, 2012, 46, e22-e22.	0.9	11
83	Therapeutic drug monitoring of antifungal agents. Laboratoriums Medizin, 2012, 36, 1-10.	0.1	0
84	Importance of Pharmacokinetic Considerations for Selecting Therapy in the Treatment of Invasive Fungal Infections. American Journal of Therapeutics, 2012, 19, 51-63.	0.5	8
85	Therapeutic Drug Monitoring of Posaconazole in Patients with Acute Myeloid Leukemia or Myelodysplastic Syndrome. Antimicrobial Agents and Chemotherapy, 2012, 56, 6298-6303.	1.4	31
86	Posaconazole Treatment in Hematology Patients. Therapeutic Drug Monitoring, 2012, 34, 320-325.	1.0	19
87	Making sense of posaconazole therapeutic drug monitoring. Current Opinion in Infectious Diseases, 2012, 25, 605-611.	1.3	31
88	Posaconazole Exposure-Response Relationship: Evaluating the Utility of Therapeutic Drug Monitoring. Antimicrobial Agents and Chemotherapy, 2012, 56, 2806-2813.	1.4	134
89	Therapeutisches Drug Monitoring von Antimykotika/Therapeutic drug monitoring of antifungal agents. Laboratoriums Medizin, 2012, 36, .	0.1	0
90	Therapeutic Drug Monitoring of Posaconazole in Allogeneic Hematopoietic Stem Cell Transplantation Patients Who Develop Gastrointestinal Graft-versus-Host Disease. Antimicrobial Agents and Chemotherapy, 2012, 56, 5247-5252.	1.4	32
91	Advances in systemic antifungal therapy. Clinics in Dermatology, 2012, 30, 657-661.	0.8	9
92	Uso actual de los antifÃºngicos triazoles en niÃ±os. Infectio, 2012, 16, 82-93.	0.4	0
93	Invasive Mycoses: Strategies for Effective Management. American Journal of Medicine, 2012, 125, S25-S38.	0.6	68
94	Systemic Antifungal Agents. , 2012, , 1971-1977.		0

#	Article	IF	Citations
95	Therapeutic drug monitoring of posaconazole in hematology adults under posaconazole prophylaxis: influence of food intake. European Journal of Clinical Microbiology and Infectious Diseases, 2012, 31, 161-167.	1.3	44
96	Antifungal therapy: current concepts and evidence-based management. Current Medical Research and Opinion, 2013, 29, 289-290.	0.9	1
97	Posaconazole Pharmacokinetics in a 2â€¥earâ€Old Boy with Rhinoâ€Cerebralâ€Orbital Zygomycosis. Pharmacotherapy, 2013, 33, e1-8.	1.2	10
98	Optimizing antifungal choice and administration. Current Medical Research and Opinion, 2013, 29, 13-18.	0.9	83
99	New antifungal antibiotics. Current Opinion in Infectious Diseases, 2013, 26, 168-174.	1.3	30
100	Antifungal Prophylaxis with Posaconazole in Patients with Acute Myeloid Leukemia: Dose Intensification Coupled with Avoidance of Proton Pump Inhibitors Is Beneficial in Shortening Time to Effective Concentrations. Antimicrobial Agents and Chemotherapy, 2013, 57, 6081-6084.	1.4	23
101	Posaconazole: A Review of Drug Interactions with HIV Antiretroviral Agents. Pharmacy (Basel,) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 502	0.6	1
102	Comparative Pharmacodynamics of Posaconazole in Neutropenic Murine Models of Invasive Pulmonary Aspergillosis and Mucormycosis. Antimicrobial Agents and Chemotherapy, 2014, 58, 6767-6772.	1.4	42
103	Optimizing azole antifungal therapy in the prophylaxis and treatment of fungal infections. Current Opinion in Infectious Diseases, 2014, 27, 493-500.	1.3	24
104	Understanding Variability in Posaconazole Exposure Using an Integrated Population Pharmacokinetic Analysis. Antimicrobial Agents and Chemotherapy, 2014, 58, 6879-6885.	1.4	65
105	Pharmacokinetics and Pharmacodynamics of Antifungals in Children and their Clinical Implications. Clinical Pharmacokinetics, 2014, 53, 429-454.	1.6	37
108	Update on Posaconazole Pharmacokinetics: Comparison of Old and New Formulations. Current Fungal Infection Reports, 2014, 8, 139-145.	0.9	14
109	Impact of structured personal on-site patient education on low posaconazole plasma concentrations in patients with haematological malignancies. International Journal of Antimicrobial Agents, 2014, 44, 140-144.	1.1	24
110	Mechanisms of Action of Antifungal Agents. , 2015, , 183-196.		0
111	Discovering of Tumorâ€targeting Peptides using Biâ€functional Microarray. Advanced Healthcare Materials, 2015, 4, 2802-2808.	3.9	14
112	Agents of Mucormycosis and Entomophthoramycosis. , 2015, , 2909-2919.e3.		11
113	Drugs Active against Fungi, Pneumocystis, and Microsporidia. , 2015, , 479-494.e4.		8
114	Posaconazole: An Update of Its Clinical Use. Pharmacy (Basel, Switzerland), 2015, 3, 210-268.	0.6	22

#	Article	IF	Citations
115	Antifungal Agents. , 2015, , 79-97.		1
116	Pharmacologic and clinical evaluation of posaconazole. Expert Review of Clinical Pharmacology, 2015, 8, 321-334.	1.3	47
117	Review of the New Delayed-Release Oral Tablet and Intravenous Dosage Forms of Posaconazole. Pharmacotherapy, 2015, 35, 208-219.	1.2	47
118	Pharmacokinetics of posaconazole prophylaxis of patients with acute myeloid leukemia. Journal of Infection and Chemotherapy, 2015, 21, 663-667.	0.8	6
119	Antifungal Drug Therapeutic Monitoring: What are the Issues?. Current Clinical Microbiology Reports, 2015, 2, 55-66.	1.8	11
120	Determination of posaconazole concentration with LCâ€"MS/MS in adult patients with hematologic malignancy. Clinica Chimica Acta, 2015, 450, 220-226.	0.5	15
121	Trypanosoma brucei CYP51: Essentiality and Targeting Therapy in an Experimental Model. PLoS Neglected Tropical Diseases, 2016, 10, e0005125.	1.3	23
122	Differences in Food Effects for 2 Weak Bases With Similar BCS Drug-Related Properties: What Is Happening in the Intestinal Lumen?. Journal of Pharmaceutical Sciences, 2016, 105, 2712-2722.	1.6	40
123	Supersaturation and Precipitation of Posaconazole Upon Entry in the Upper Small Intestine in Humans. Journal of Pharmaceutical Sciences, 2016, 105, 2677-2684.	1.6	92
124	Posaconazole plasma exposure correlated to intestinal mucositis in allogeneic stem cell transplant patients. European Journal of Clinical Pharmacology, 2016, 72, 953-963.	0.8	21
125	Gastrointestinal and Systemic Monitoring of Posaconazole in Humans After Fasted and Fed State Administration of a Solid Dispersion. Journal of Pharmaceutical Sciences, 2016, 105, 2904-2912.	1.6	43
126	Treatment of Disseminated Aspergillosis with Posaconazole in 10 Dogs. Journal of Veterinary Internal Medicine, 2016, 30, 167-173.	0.6	25
127	Azole Antifungal Agents. , 2016, , 77-96.		0
128	Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America. Clinical Infectious Diseases, 2016, 62, e1-e50.	2.9	2,489
129	Posaconazole plasma concentration in pediatric patients receiving antifungal prophylaxis after allogeneic hematopoietic stem cell transplantation. Medical Mycology, 2016, 54, 128-137.	0.3	17
130	Impact of Mucositis on Absorption and Systemic Drug Exposure of Isavuconazole. Antimicrobial Agents and Chemotherapy, 2017, 61, .	1.4	52
131	Pharmacokinetics of antifungal drugs: practical implications for optimized treatment of patients. Infection, 2017, 45, 737-779.	2.3	236
132	Therapeutic drug monitoring for invasive mould infections and disease: pharmacokinetic and pharmacodynamic considerations. Journal of Antimicrobial Chemotherapy, 2017, 72, i12-i18.	1.3	90

#	Article	IF	Citations
133	CYP51 as drug targets for fungi and protozoan parasites: past, present and future. Parasitology, 2018, 145, 1820-1836.	0.7	81
134	Antifungal Agents. , 2018, , 425-501.		0
135	Interplay of Supersaturation and Solubilization: Lack of Correlation between Concentration-Based Supersaturation Measurements and Membrane Transport Rates in Simulated and Aspirated Human Fluids. Molecular Pharmaceutics, 2019, 16, 5042-5053.	2.3	40
136	Plasma exposures following posaconazole delayed-release tablets in immunocompromised children and adolescents. Journal of Antimicrobial Chemotherapy, 2019, 74, 3573-3578.	1.3	13
137	Advances in pediatric antimicrobial agents development. Current Opinion in Pediatrics, 2019, 31, 135-143.	1.0	3
138	Using State Transition Models To Explore How the Prevalence of Subtherapeutic Posaconazole Exposures Impacts the Clinical Utility of Therapeutic Drug Monitoring for Posaconazole Tablets and Oral Suspension. Antimicrobial Agents and Chemotherapy, 2019, 63, .	1.4	8
139	Clinical Pharmacokinetics and Dose Recommendations for Posaconazole in Infants and Children. Clinical Pharmacokinetics, 2019, 58, 53-61.	1.6	35
140	History of the development of antifungal azoles: A review on structures, SAR, and mechanism of action. Bioorganic Chemistry, 2020, 104, 104240.	2.0	129
141	Posaconazole in prophylaxis and treatment of invasive fungal infections: a pharmacokinetic, pharmacodynamic and clinical evaluation. Expert Opinion on Drug Metabolism and Toxicology, 2020, 16, 539-550.	1.5	12
142	Administration and Dosing of Systemic Antifungal Agents in Pediatric Patients. Paediatric Drugs, 2020, 22, 165-188.	1.3	18
143	Evaluation of target attainment of oral posaconazole suspension in immunocompromised children. Journal of Antimicrobial Chemotherapy, 2020, 75, 726-729.	1.3	8
144	A Population Pharmacokinetic Modeling and Simulation Study of Posaconazole Oral Suspension in Immunocompromised Pediatric Patients: A Short Communication. Therapeutic Drug Monitoring, 2021, 43, 512-518.	1.0	9
145	Review of Pharmacologic Considerations in the Use of Azole Antifungals in Lung Transplant Recipients. Journal of Fungi (Basel, Switzerland), 2021, 7, 76.	1.5	12
146	Pharmacokinetics and target attainment of intravenous posaconazole in critically ill patients during extracorporeal membrane oxygenation. Journal of Antimicrobial Chemotherapy, 2021, 76, 1234-1241.	1.3	14
147	Novel Antifungal Therapies. , 2007, , 69-98.		2
148	Azoles. , 2011, , 61-93.		1
149	Rational Approach to Pediatric Antifungal Therapy. Advances in Experimental Medicine and Biology, 2011, 697, 231-242.	0.8	2
151	Antimicrobial Agents, Drug Adverse Reactions and Interactions, and Cancer. Cancer Treatment and Research, 2014, 161, 413-462.	0.2	4

#	Article	IF	Citations
152	Invasive fungal infections in children: advances and perspectives. , 2007, , 405-472.		1
153	Systemic Antifungal Agents. , 2010, , 549-563.		5
154	Agents of Mucormycosis and Entomophthoramycosis. , 2010, , 3257-3269.		22
155	Invasive Aspergillosis in Malignancy and Stem Cell Transplant Recipients. , 0, , 519-530.		6
156	Antifungals: Drug Class, Mechanisms of Action, Pharmacokinetics/Pharmacodynamics, Drug-Drug Interactions, Toxicity, and Clinical Use. , 0, , 343-371.		3
158	Drug Interaction Profile of Posaconazole. Internet Journal of Allied Health Sciences and Practice, 2008, , .	0.2	0
159	Azoles. , 2009, , 230-262.		0
160	Newer Antifungal Agents in Pediatrics. , 2009, , 414-426.		0
161	Pharmacology of Azole Antifungal Agents. , 2009, , 199-218.		0
162	Posaconazole. Journal of Postgraduate Medicine, 2010, 56, 163-167.	0.2	2
164	Antifungal Therapy in Patients with Hematological Malignancies. , 2011, , 569-588.		0
165	Antifungal Agents. , 2011, , 509-560.		0
168	15 Antifungal Pharmacokinetics. , 2014, , 281-290.		0
169	Azoles. , 0, , 417-434.		0
170	Antifungal Agents. , 0, , 2221-2235.		0
172	Role of posaconazole in the management of oropharyngeal and esophageal candidiasis. Therapeutics and Clinical Risk Management, 2007, 3, 533-42.	0.9	9
173	Evaluating posaconazole, its pharmacology, efficacy and safety for the prophylaxis and treatment of fungal infections. Expert Opinion on Pharmacotherapy, 2022, 23, 175-199.	0.9	6
174	The Overview on the Pharmacokinetic and Pharmacodynamic Interactions of Triazoles. Pharmaceutics, 2021, 13, 1961.	2.0	20

#	Article	IF	Citations
175	Azoles. , 2021, , .		2
176	Azole Therapeutic Drug Monitoring and its Use in the Management of Invasive Fungal Disease. Current Fungal Infection Reports, 0, , 1.	0.9	3
178	Long-term treatment of refractory invasive fungal infection with posaconazole: additive value of therapeutic drug monitoring. Acta Clinica Belgica, 2011, 66, 231-2.	0.5	1
179	Chemical and biological aspects of posaconazole as a classic antifungal agent with non-classical properties: highlighting a tetrahydrofuran-based drug toward generation of new drugs. Medicinal Chemistry Research, 2022, 31, 833-850.	1.1	1
180	Challenges in the Treatment of Invasive Aspergillosis in Immunocompromised Children. Antimicrobial Agents and Chemotherapy, 2022, 66, .	1.4	8
181	Population pharmacokinetics of posaconazole in Chinese pediatric patients with acute leukaemia: Effect of food on bioavailability and dose optimization. European Journal of Pharmaceutical Sciences, 2022, 178, 106289.	1.9	0
182	A Physiologically-Based Pharmacokinetic Model of Ruxolitinib and Posaconazole to Predict CYP3A4-Mediated Drugâ€"Drug Interaction Frequently Observed in Graft versus Host Disease Patients. Pharmaceutics, 2022, 14, 2556.	2.0	2
183	Integrating Forward and Reverse Translation in PBPK Modeling to Predict Food Effect on Oral Absorption of Weakly Basic Drugs. Pharmaceutical Research, 2023, 40, 405-418.	1.7	0